edrophonium has been researched along with Parkinson Disease in 2 studies
Edrophonium: A rapid-onset, short-acting cholinesterase inhibitor used in cardiac arrhythmias and in the diagnosis of myasthenia gravis. It has also been used as an antidote to curare principles.
edrophonium : A quaternary ammonium ion that is N-ethyl-N,N-dimethylanilinium in which one of the meta positions is substituted by a hydroxy group. It is a reversible inhibitor of cholinesterase, with a rapid onset (30-60 seconds after injection) but a short duration of action (5-15 minutes). The chloride salt is used in myasthenia gravis both diagnostically and to distinguish between under- or over-treatment with other anticholinesterases. It has also been used for the reversal of neuromuscular blockade in anaesthesia, and for the management of poisoning due to tetrodotoxin, a neuromuscular blocking toxin found in puffer fish and other marine animals.
Parkinson Disease: A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75)
| Excerpt | Relevance | Reference |
|---|---|---|
| " Patients with PD+NOH had normal bradycardia responses to edrophonium and normal epinephrine responses to glucagon." | 3.74 | Generalized and neurotransmitter-selective noradrenergic denervation in Parkinson's disease with orthostatic hypotension. ( Goldstein, DS; Holmes, C; Imrich, R; Pechnik, S; Sharabi, Y, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (50.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Sharabi, Y | 1 |
| Imrich, R | 1 |
| Holmes, C | 1 |
| Pechnik, S | 1 |
| Goldstein, DS | 1 |
| Gilbert, JC | 1 |
2 other studies available for edrophonium and Parkinson Disease
| Article | Year |
|---|---|
Generalized and neurotransmitter-selective noradrenergic denervation in Parkinson's disease with orthostatic hypotension.
Topics: Aged; Blood Pressure; Bradycardia; Cholinesterase Inhibitors; Edrophonium; Epinephrine; Female; Gluc | 2008 |
Diseases of the central nervous system. Pharmacological basis of treatment.
Topics: Amantadine; Analgesics, Opioid; Anticonvulsants; Blood-Brain Barrier; Central Nervous System Disease | 1975 |